The role of circulating dendritic cells in patients with unresectable pancreatic cancer

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3827-3834

  Hirooka, Satoshi ^a   Yanagimoto, Hiroaki ^a   Satoi, Sohei ^a   Yamamoto, Tomohisa ^a   Toyokawa, Hideyoshi ^a   Yamaki, So ^a   Rintaro, Yui ^a   Inoue, Kentaro ^a   Michiura, Taku ^a   Kwon, A Hon ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Circulating dendritic cells; Dentritic cells; Myeloid DC; Pancreatic cancer; Prognostic factor; Survival analysis

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; GIMERACIL; OTERACIL POTASSIUM; PEPTIDE VACCINE; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; DISTANT METASTASIS; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 83055195511     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ministry of Health, Labour and Welfare: Dynamic of population statistics 2009 in Japan.
2. Warshaw AL and Fernadez-del Castillo C: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
3. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392(6673): 245-252, 1998. (Pubitemid 28155090)
4. + subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol 163(3): 1409-1419, 1999.
5. Reid SD, Penna G and Adorini L: The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 12(1): 114-121, 2000. (Pubitemid 30093459)
6. Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N, Kwon AH and Kamiyama Y: Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 114(1): 52-60, 2005. (Pubitemid 39642790)
7. Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Yamao J, Kim S, Terakawa N, Takahashi K and Kwon AH: Circulating Myeloid Dendritic Cells as Prognostic Factors in Patients with Pancratic Cancer Who Have Undergone Surgical Resection. J Surg Res 2010 (in press) doi:10.1016/j.jss.2010.09.027
8. National Complehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Ver2.2011, Pancreatic Adenocarcinoma.
9. Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, Takahashi K, Nakahara K, Honma S, Tanaka M, Mizoguchi J, Yamada A, Oka M, Kamiyama Y, Itoh K and Takai S: Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98(4): 605-611, 2007. (Pubitemid 46562753)
10. UICC TNM Classification of Malignant Tumors, 6th Ed. Sobin L and Wittekind C. (eds.) New York: Wiley-Liss, 2002.
11. Ahrendt SA and Pitt HA: Surgical management of pancreatic cancer. Oncology 16: 725-734, 2002.
12. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP and Talamonti MS: Validation of the 6th Edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738-744, 2007. (Pubitemid 47257648)
13. Katz MHG, Hwang R, Fleming JB and Evans DB: Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 58: 111-125, 2008. (Pubitemid 351521866)
14. Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ and Freemantle N: Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer 99: 883-893, 2008.
15. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A and Topuz E: Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. J Clin Oncol 24(6): 547-550, 2001. (Pubitemid 33131412)
16. Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA and Crane CH: Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107(11): 2589-2596, 2006. (Pubitemid 44845612)
17. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Jöhnk C, Henne-Bruns D, Kremer B and Kalthoff H: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7: 925-932, 2001.
18. Takahashi K, Toyokawa H, Takai S, Satoi S, Yanagimoto H, Terakawa N, Araki H, Kwon AH and Kamiyama Y: Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother 55(7): 775-784, 2006.
19. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K and Fukuhara S: Differential regulation of human blood dendrtic cell subsets by IFNs. J Immunol 166(5): 2961-2969, 2001. (Pubitemid 33117291)
20. Gillet M and Liu YJ: Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195(6): 695-704, 2002.
21. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP and Ghaneh P: Meta-Analysis of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. J Clin Oncol 25: 2607-2615, 2007. (Pubitemid 47041235)
22. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, Grosse-Wilde H, Broelsch CE, Gerken G and Cicinnati VR: Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 10: 7260-7269, 2004. (Pubitemid 39487713)
23. Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, Valerio D and Eremin O: Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 53: 510-518, 2004. (Pubitemid 38680257)
24. Hoffmann TK, Müller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ and Whiteside TL: Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8: 1787-1793, 2002. (Pubitemid 34633736)
25. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP and Gabrilovich DI: Clinical Significance of Defective Dendritic Cell Differentiation in Cancer. Clin Cancer Res 6: 1755-1766, 2000. (Pubitemid 30305068)
26. Tjomsland V, Sandström P, Spångeus A, Messmer D, Emilsson J, Falkmer U, Falkmer S, Magnusson KE, Borch K and Larsson M: Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmatcytoid dendritic cells: an indicator of disease severity? BMC Cancer 10: 87, 2010.
27. + dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol 39(12): 797-806, 2009.
28. Bold RJ, Chandra J and McConkey DJ: Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by BCL-2 content. Ann Surg Oncol 6(3): 279-285, 1999. (Pubitemid 29221014)
29. Yanagmoto H, Satoi S, Mine T, Tanaka K, Yamada A, Oka M and Itoh K: A multicenter phase I/II study of gemcitabine and personalized peptide vaccination combination therapy for metastatic pancreatic cancer patients. May 30-Jun 3, Chicago, IL. 2008 ASCO Annual Meeting.
30. AbdAlla EE, Blair GE, Jones RA, Sue-Ling HM and Johnston D: Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 87: 489-496, 1995.
31. Aquino A, Prete SP, Greiner JW, Giuliani A, Graziani G, Turriziani M, De Filippi R, Masci G, Bonmassar E and De Vecchis L: Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoemboryonic antigen expression in colon cancer cells. Clin Cancer Res 4: 2473-2481, 1998. (Pubitemid 28477914)
32. Chu Y, Wang LX, Yang G, Ross HJ, Urba WJ, Prell R, Jooss K, Xiong S and Hu HM: Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 29: 367-380, 2006. (Pubitemid 44288949)
33. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI and Jaffee EM: Cyclophosphamide doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in Her-2/neu tolerized mice. Cancer Res 61: 3689-3697, 2001. (Pubitemid 32694981)
34. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, Gon G, Toyoda M and Tanigawa N: Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104(1): 92-97, 2002. (Pubitemid 36184151)
35. Sandel MH, Dadabayev AR and Menon AG: Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: Role of maturation status and intratumoral lacalization. Clin Cancer Res 11(7): 2576-2582, 2005. (Pubitemid 40569456)
36. Ambe K, Mori M and Enjoji M: S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63(3): 496-503, 1989. (Pubitemid 19038466)